As evidenced by phase 2 data presented at ACG 2023, mirikizumab sustains PRO Remission for Crohn's disease and CDAI.

Published Date: 26 Oct 2023

Mirikizumab's favorable safety and efficacy profiles were demonstrated by the results of the 104-week extension study, which were presented at ACG 2023.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

2.

Detecting pancreatic cancer through changes in body composition and metabolism

3.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

4.

The pandemic had little impact on mental health symptoms.

5.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot